PNT News and Press, POINT Biopharma Global Inc. From 05/16/22

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy INDIANAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma G...

POINT Biopharma Global press release (NASDAQ:PNT): Q1 GAAP EPS of -$0.18 beats by $0.08. As of March 31, 2022, POINT had approximately $227.4 million in cash and cash equivalents, which is anticipated to fund operations into the first quarter of 2024. For further details see: POINT Biop...

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fi...

INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinica...

POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer I...

POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy is planned for summer 2022 INDIANAPOLIS, April 11, 2022 (GLOBE NEWSW...

POINT Biopharma Global press release (NASDAQ:PNT): Q4 GAAP EPS of -$0.16 beats by $0.12. As of December 31, 2021, cash and cash equivalents of $238.8M For further details see: POINT Biopharma Global GAAP EPS of -$0.16 beats by $0.12

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alp...

INDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that a recent reactor...

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals Register online at https://hub.pointbiopharma.com/dosimetry INDIANAPOLIS, March 15, 2022 (G...